ReviewCurrent opinion in endocrinology, diabetes, and obesity2015
Update on primary ovarian insufficiency.
Review in Current opinion in endocrinology, diabetes, and obesity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Effect of fennel extract on Anti-Müllerian Hormone and sonographic indices in infertile women with occult premature ovarian insufficiency: a randomized controlled clinical trial.BMC complementary medicine and therapies · 2025Trial
- [Stem cell therapy for premature ovarian insufficiency: a review of clinical evidence and therapeutic strategies].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Mechanism of platelet-rich plasma in improving cyclophosphamide-induced premature ovarian failure in rats.Stem cell research & therapy · 2025Article
- Plasma-derived exosomal miRNA profiles reveal potential epigenetic pathogenesis of premature ovarian failure.Human genetics · 2024Article
- Effect of moxibustion on expression profile of miRNAs in Tripterygium glycoside-induced decreased ovarian reserve.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Article
- Meta-analysis highlight the therapeutic potential of stem cells for premature ovarian failure.Regenerative therapy · 2024Review
- The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure.Stem cell reviews and reports · 2023Review
- Current understanding of the genomic abnormities in premature ovarian failure: chance for early diagnosis and management.Frontiers in medicine · 2023Review
- Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Infertility Due to Premature Ovarian Failure.Cureus · 2022Review
- Interaction between cigarette smoking and genetic polymorphisms on the associations with age of natural menopause and reproductive lifespan: the Singapore Chinese Health Study.Human reproduction (Oxford, England) · 2022Article
- Nrf2 Signaling Pathway Mediates the Protective Effects of Daphnetin Against D-Galactose Induced-Premature Ovarian Failure.Frontiers in pharmacology · 2022Article
- Complementary and Alternative Medicine for Premature Ovarian Insufficiency: A Review of Utilization and Mechanisms.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure.Stem cell research & therapy · 2021Review
- Regenerative Medicine Approaches in Bioengineering Female Reproductive Tissues.Reproductive sciences (Thousand Oaks, Calif.) · 2021Review
- Effects of Environmental Endocrine-Disrupting Chemicals on Female Reproductive Health.Advances in experimental medicine and biology · 2021Article
- Creation of a Bioengineered Ovary: Isolation of Female Germline Stem Cells for the Repopulation of a Decellularized Ovarian Bioscaffold.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Decellularization Methods of Ovary in Tissue Engineering.Advances in experimental medicine and biology · 2021Article
- An exploration of factors affecting the quality of life of women with primary ovarian insufficiency: a qualitative study.BMC women's health · 2020Article
- Whole-ovary decellularization generates an effective 3D bioscaffold for ovarian bioengineering.Journal of assisted reproduction and genetics · 2020Article
- Bioengineering the ovary to preserve and reestablish female fertility.Animal reproduction · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewDespite an incidence of 1% among women under the age of 40, primary ovarian insufficiency (POI) is still poorly understood. As the variable cause and presentation of POI complicate its management, a standard regimen for treatment remains to be established. However, emerging research has provided new insight on current mainstays of treatment as well as novel management approaches and therapeutic interventions. RECENT
findingsRecent clinical trials in women with POI indicate that the widely used regimen of transdermal estradiol and medroxyprogesterone acetate restores bone mineral density to a level equal to women with normal ovarian function. Further research verifies that compounded bioidentical hormones and androgen supplementation are inadequate in treating POI and lowering risk for long-term sequelae. Additionally, assessing changes in bone turnover markers may be useful for monitoring bone mineral density. Alternative therapies such as acupuncture, dehydroepiandrosterone, and bupropion may be effective in treating the effects of estrogen deficiency at some level, but require further investigation. SUMMARY: Recent updates show promise in improving management methods and reducing risk of long-term sequelae. Additional research that expands upon the most current literature is critical to achieve an evidence-based standard of best practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.